Skip to content
sellWeak cluster of 210b5-1 plan

Mark C. Schneyer sold $83k of ACAD

EVP, CHIEF FINANCIAL OFFICER at ACADIA PHARMACEUTICALS INC. 3,498 shares at an average of $23.65, traded Sep 15, 2025, filed Sep 16, 2025.

Warning score
19
Value
$83k
3,498 shares
Holdings after
43,447
-7% from before
From 52-week low
+75%
low $14.10, close $24.67
From 52-week high
-7%
high $26.57, as of Sep 15, 2025

Score components

  • Role
    CFO
    +22
  • Trade size
    $83k at market
    +9
  • Share of holdings sold
    Sold 7.5% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ACADOct 9, 2026 · close 19.78
Since filing Sep 16, 2025: -17.4%SPY +19.6% · excess -37.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001899977-25-000004, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 12, 2025AGrant or award
Common Stock
+6,815$0.00$046,945Sep 16, 2025
Sep 15, 2025SOpen-market sale
Common Stock10b5-1
-3,498$23.65$83k43,447Sep 16, 2025

Related signals

Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
14Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
Jennifer J Rhodes
EVP, CHIEF LEGAL OFFICER, SEC
$83k
3,844 shares
-25%
1Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$42k
1,942 shares
-7%
28Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
Adams Catherine Owen
Chief Executive Officer
$250k
11,641 shares
-44%
23Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
Elizabeth H.Z. Thompson
EVP, Head of Research & Dev
$74k
3,435 shares
-51%
18Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$159k
7,385 shares
-12%
1Weak
ACADsell10b5-1
ACADIA PHARMACEUTICALS INC
Jennifer J Rhodes
EVP, CHIEF LEGAL OFFICER, SEC
$162k
6,950 shares
-48%
10Weak
ACADsell 310b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$97k
4,084 shares
-14%
20Weak
ACADsell 310b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$243k
10,262 shares
-16%
70Notable
ACADsell 3
ACADIA PHARMACEUTICALS INC
James M Daly
director
$671k
30,000 shares
-88%
29Weak
ACADsell 2
ACADIA PHARMACEUTICALS INC
Elizabeth A. Garofalo
director
$42k
1,600 shares
-6%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Mark C. Schneyer sold $83k of ACAD | InsiderTell